Optimal Strategy for Colorectal Cancer Patients’ Diagnosis Based on Circulating Tumor Cells and Circulating Tumor Endothelial Cells by Subtraction Enrichment and Immunostaining-Fluorescence In Situ Hybridization Combining with CEA and CA19-9

Table 2

The results of CTC, CTEC, CEA, and CA19-9 levels between CRC patients and controls.

Groups	CRC patients (n = 115)	Controls (n = 20)	value	Sensitivity	Specificity
CTCs			<0.001	0.878	0.900
Positive	101 (87.8%)	2 (10.0%)
Negative	14 (12.2%)	18 (90.0%)
CTECs			<0.001	0.391	1
Positive	45 (39.1%)	0 (0%)
Negative	70 (60.9%)	20 (100%)
CEA			0.004	0.287	1
Positive	33 (28.7%)	0 (0%)
Negative	82 (71.3%)	20 (100%)
CA19-9			0.044	0.261	0.950
Positive	30 (26.1%)	1 (5.0%)
Negative	85 (73.9%)	19 (95.0%)

CTC and CTEC positive: ≥1 CTC/7.5 mL, CEA positive: >10.9 ng/mL, and CA19-9: >37 U/mL.